SLC6A3 and Parkinson disease: Using a reverse translation strategy, we tested the hypothesis that in PD mice an analogous pharmacological approach such as L-DOPA+ carbidopa/benserazide administration173–183 would lower PBMCs expressing DAT and TH towards sham control levels.